At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,494 enrolled
Drug / intervention
RPC1063drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
In Brief
A Phase 3 clinical trial evaluating RPC1063 for Multiple Sclerosis. Completed, enrolled 2,494 participants across 175 sites in 26 countries.
Detailed Summary
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesBelarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionJan 2023
TodayJul 2026
First PostedOct 15, 2015
Enrollment StartOct 16, 2015
Primary CompletionJan 5, 2023
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 10.7 years ago
Interventions
RPC1063drug